000075966 001__ 75966
000075966 005__ 20200117221603.0
000075966 0247_ $$2doi$$a10.1038/s41416-018-0293-5
000075966 0248_ $$2sideral$$a109093
000075966 037__ $$aART-2018-109093
000075966 041__ $$aeng
000075966 100__ $$aGarcía-Foncillas, J.
000075966 245__ $$aProspective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
000075966 260__ $$c2018
000075966 5060_ $$aAccess copy available to the general public$$fUnrestricted
000075966 5203_ $$aBackground: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented.
Methods: Circulating cell-free DNA from plasma was examined for RAS mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient.
Results: The overall percentage agreement between plasma-based and tissue-based RAS mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689–0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue RAS results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease.
Conclusions: In this first prospective real-world RAS mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of RAS mutation status to determine mCRC patient eligibility for anti-EGFR therapy.
000075966 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-sa$$uhttp://creativecommons.org/licenses/by-nc-sa/3.0/es/
000075966 590__ $$a5.416$$b2018
000075966 591__ $$aONCOLOGY$$b44 / 229 = 0.192$$c2018$$dQ1$$eT1
000075966 592__ $$a2.848$$b2018
000075966 593__ $$aOncology$$c2018$$dQ1
000075966 593__ $$aCancer Research$$c2018$$dQ1
000075966 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000075966 700__ $$aTabernero, J.
000075966 700__ $$aÉlez, E.
000075966 700__ $$aAranda, E.
000075966 700__ $$aBenavides, M.
000075966 700__ $$aCamps, C.
000075966 700__ $$aJantus-Lewintre, E.
000075966 700__ $$aLópez, R.
000075966 700__ $$aMuinelo-Romay, L.
000075966 700__ $$aMontagut, C.
000075966 700__ $$0(orcid)0000-0002-9159-4988$$aAntón, A.$$uUniversidad de Zaragoza
000075966 700__ $$aLópez, G.
000075966 700__ $$aDíaz-Rubio, E.
000075966 700__ $$aRojo, F.
000075966 700__ $$aVivancos, A.
000075966 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000075966 773__ $$g119 (2018), 1464-1470$$pBr. J. Cancer$$tBRITISH JOURNAL OF CANCER$$x0007-0920
000075966 8564_ $$s355014$$uhttps://zaguan.unizar.es/record/75966/files/texto_completo.pdf$$yVersión publicada
000075966 8564_ $$s9931$$uhttps://zaguan.unizar.es/record/75966/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000075966 909CO $$ooai:zaguan.unizar.es:75966$$particulos$$pdriver
000075966 951__ $$a2020-01-17-21:44:06
000075966 980__ $$aARTICLE